Im Cannabis Corp Stock Price, News & Analysis

IM Cannabis (NASDAQ: IMCC) will report operational and financial results for the third quarter 2025, which ended September 30, 2025.

The company said results will be released on Thursday, November 13, 2025, before the market opens. IM Cannabis operates in Israel and Germany.

IM Cannabis (NASDAQ: IMCC) announced that Chief Financial Officer Uri Birenberg will step down for personal reasons, remaining in the role through January 5, 2026 or an earlier date as determined by the company.

Mr. Birenberg will assist in a structured transition until a successor is appointed. The company noted his two-year tenure and the CEO expressed thanks for his contributions.

IM Cannabis (NASDAQ: IMCC) announced on Oct 23, 2025 a non-binding term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million.

Consideration may include cash, IMC shares and performance-linked earn-outs. The deal is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions, and may not be completed as proposed. The move follows IMC's exploration of additional business activities to enhance long-term growth and shareholder value.

IM Cannabis (NASDAQ:IMCC), a medical cannabis company operating in Israel and Germany, announced significant changes to its Board of Directors effective September 15, 2025. The company appointed Asaf Yitzhaik and Eli Zamir to replace departing board members Shmulik Arbel and Brian Schinderle.

Oz Adler has been appointed as the new Chairman of the Board, replacing Oren Shuster, who continues as CEO and director. The new board members bring extensive experience in retail, real estate, finance, and capital markets. Additionally, the company announced plans to explore new business opportunities to enhance growth and shareholder value.

IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq on September 4, 2025 that it now meets the minimum stockholders' equity requirement of $2.5 million under Rule 5550(b)(1). As a result, IMCC's common stock will maintain its listing and continue trading on the Nasdaq Capital Market.

IM Cannabis (NASDAQ: IMCC) has announced key amendments to its November 2024 Warrants and filed a Form F-3 Resale Registration Statement. The company has agreed to reduce the exercise price of the November 2024 Warrants from C$4.32 to C$3.43 and extend their expiration date from November 12, 2026 to July 31, 2030.

The Form F-3 Registration Statement covers 4,982,517 Common Shares, including shares issuable upon exercise of various warrants. The transaction involves participation from company insiders, including CEO Oren Shuster, director Shmulik Arbel, and insider Rafael Gabay, constituting a related party transaction under MI 61-101.

IM Cannabis (NASDAQ: IMCC) reported mixed Q2 2025 financial results, with revenue declining 14% to $12.7 million compared to Q2 2024, primarily due to war-related challenges in Israel and supply chain delays impacting approximately $5 million in revenue.

Despite revenue headwinds, the company demonstrated significant profitability improvements with a 306% increase in gross profit to $3.4 million and gross margin expansion to 27% from 6% year-over-year. The company achieved EBITDA profitability of $0.1 million, compared to a $2.3 million loss in Q2 2024, while maintaining stable operating expenses at $3.8 million.

The quarter saw accelerated growth in Germany of $3.3 million, offset by a $5.3 million decrease in Israel. Cash position stood at $0.8 million as of June 30, 2025, with total assets of $41.1 million and liabilities of $37 million.

IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has scheduled its Q2 2025 financial results announcement for Tuesday, August 12, 2025, before market opening. The results will cover the period ended June 30, 2025.

IM Cannabis (NASDAQ: IMCC) has successfully closed a private placement offering, raising gross proceeds of approximately US$4.1 million. The company issued 2,050,000 units at C$2.7427 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.

The warrants have an exercise price of C$3.43 and a 60-month term. The company plans to use the proceeds for working capital, debt repayment, and general corporate purposes. Pure Equity Ltd. acted as a consultant for the offering.

IM Cannabis has committed to filing a resale registration statement within 30 days of closing, with effectiveness targeted within 60-90 days depending on SEC review.